{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:06:23Z","timestamp":1793088383441,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Therapy-related acute myeloid leukemia (AML; tAML) is one of the most feared therapy-emergent complications. This study aims to determine the clinical and pathological significance and define therapeutic implications and poor prognosticators in pediatric tAML. We analyzed a total of 119 pediatric patients (aged 2-20 years) who were centrally diagnosed with tAML within the Acute Myeloid Leukemia Berlin-Frankfurt-M\u00fcnster (AML-BFM) study group between 1993 and 2019. Compared with de novo AML, tAML was associated with decreased white blood count and involvement of the central nervous system. Latency to tAML was inversely correlated with age at primary malignancy. Patients with tAML were more likely to have abnormal karyotypes, overrepresenting KMT2A rearrangements, the unfavorable cytogenetics \u20137\/del(7q), as well as complex and monosomal karyotypes, whereas core-binding AML was underrepresented. The occurrence of stratification-relevant molecular genetics was comparable with de novo AML, whereas CEBPAdm was absent in tAML. Survival rates in tAML improved from 10% \u00b1 6% in AML-BFM 1993\/1998 to 50% \u00b1 10% in the registries 2012\/2017; however, this is still worse than de novo AML. Hematopoietic stem cell transplantation (HSCT) in no evidence of leukemia (NEL; &amp;lt;5% blasts) after 2 induction cycles greatly improved survival. Adverse cytogenetics, previous ionizing radiation (&amp;gt;35 Gy), and latency \u22641 year were identified as the strongest poor prognosticators. Over the past 26 years, outcome and survival significantly improved in pediatric tAML. Our results suggest that HSCT in NEL after 2 induction cycles is the most promising therapeutic approach for achieving improved survival. Radiation, adverse cytogenetics, and latency \u22641 year should be considered as poor prognosticators in pediatric tAML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014728","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:09:12Z","timestamp":1739956152000},"page":"2831-2841","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3139-8747","authenticated-orcid":false,"given":"Stephanie","family":"Sendker","sequence":"first","affiliation":[{"name":"1Department of Pediatric Hematology and Oncology, West German Cancer Centre, University Medicine Essen, Essen, Germany"},{"name":"2German Cancer Consortium (DKTK), National Centre for Tumor Diseases (NCT), University Hospital Essen, Essen, Germany"},{"name":"3AML-BFM Study Group, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6634-4306","authenticated-orcid":false,"given":"Markus","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Hematology and Oncology, West German Cancer Centre, University Medicine Essen, Essen, Germany"},{"name":"2German Cancer Consortium (DKTK), National Centre for Tumor Diseases (NCT), University Hospital Essen, Essen, Germany"},{"name":"3AML-BFM Study Group, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-2865","authenticated-orcid":false,"given":"Evangelia","family":"Antoniou","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Hematology and Oncology, West German Cancer Centre, University Medicine Essen, Essen, Germany"},{"name":"2German Cancer Consortium (DKTK), National Centre for Tumor Diseases (NCT), University Hospital Essen, Essen, Germany"},{"name":"3AML-BFM Study Group, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-5189","authenticated-orcid":false,"given":"Daniel","family":"Neumann","sequence":"additional","affiliation":[{"name":"4Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5032-4789","authenticated-orcid":false,"given":"Naghmeh","family":"Niktoreh","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Hematology and Oncology, West German Cancer Centre, University Medicine Essen, Essen, Germany"},{"name":"2German Cancer Consortium (DKTK), National Centre for Tumor Diseases (NCT), University Hospital Essen, Essen, Germany"},{"name":"3AML-BFM Study Group, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-7860","authenticated-orcid":false,"given":"Uta","family":"Dirksen","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Hematology and Oncology, West German Cancer Centre, University Medicine Essen, Essen, Germany"},{"name":"2German Cancer Consortium (DKTK), National Centre for Tumor Diseases (NCT), University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4138-5341","authenticated-orcid":false,"given":"Nils","family":"von Neuhoff","sequence":"additional","affiliation":[{"name":"1Department of Pediatric Hematology and Oncology, West German Cancer Centre, University Medicine Essen, Essen, Germany"},{"name":"2German Cancer Consortium (DKTK), National Centre for Tumor Diseases (NCT), University Hospital Essen, Essen, Germany"},{"name":"3AML-BFM Study Group, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0045-6668","authenticated-orcid":false,"given":"Ursula","family":"Creutzig","sequence":"additional","affiliation":[{"name":"3AML-BFM Study Group, Essen, Germany"},{"name":"5Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7027-4483","authenticated-orcid":false,"given":"Dirk","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"3AML-BFM Study Group, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0838-6326","authenticated-orcid":false,"given":"Katharina","family":"Waack","sequence":"additional","affiliation":[{"name":"3AML-BFM Study Group, Essen, Germany"},{"name":"6Pediatric Research Network, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"9","key":"2025062010112412300_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2025062010112412300_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"2025062010112412300_bib3","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2025062010112412300_bib4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","volume":"108","author":"Nilsson","year":"2023","journal-title":"Haematologica"},{"key":"2025062010112412300_bib5","doi-asserted-by":"crossref","first-page":"103607","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2025062010112412300_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"31","key":"2025062010112412300_bib7","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025062010112412300_bib8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2025062010112412300_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/MPH.0b013e3181ba43dc","article-title":"Pediatric therapy-related myelodysplastic syndrome\/acute myeloid leukemia: the MD Anderson Cancer Center experience","volume":"31","author":"Aguilera","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"2025062010112412300_bib10","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.2004.99.301","article-title":"Prognosis in therapy-related acute myeloid leukemia and impact of karyotype","volume":"22","author":"Kern","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025062010112412300_bib11","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/MPH.0000000000001019","article-title":"Therapy-related acute myeloid leukemia after the treatment of primary solid cancer in children: a single-center experience","volume":"40","author":"Hong","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"2025062010112412300_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2025062010112412300_bib13","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025062010112412300_bib14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/cancers15030734","article-title":"Pediatric acute myeloid leukemia post cytotoxic therapy-retrospective analysis of the patients treated in Poland from 2005 to 2022","volume":"15","author":"Czoga\u0142a","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"suppl 11","key":"2025062010112412300_bib15","first-page":"316A","article-title":"Secondary acute myeloid leukemia following primary malignancies in childhood [abstract]","volume":"96","author":"Creutzig","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2025062010112412300_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","article-title":"Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from study AML-BFM 2004","volume":"122","author":"Creutzig","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2025062010112412300_bib17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41375-023-01919-8","article-title":"RUNX1 mutation has no prognostic significance in pediatric AML: a retrospective study of the AML-BFM Study Group","volume":"37","author":"Sendker","year":"2023","journal-title":"Leukemia"},{"issue":"10","key":"2025062010112412300_bib18","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"issue":"27","key":"2025062010112412300_bib19","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1200\/JCO.2006.06.5037","article-title":"Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98","volume":"24","author":"Creutzig","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025062010112412300_bib20","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","article-title":"Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98","volume":"28","author":"von Neuhoff","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025062010112412300_bib21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025062010112412300_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-020-0316-3","article-title":"Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype","volume":"10","author":"Samra","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"2025062010112412300_bib23","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/bloodadvances.2018026112","article-title":"Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)","volume":"3","author":"Yin","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2025062010112412300_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/asheducation.V2016.1.24.088333","article-title":"Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?","volume":"2016","author":"Heuser","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"14","key":"2025062010112412300_bib25","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/cncr.24367","article-title":"Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia","volume":"115","author":"Borthakur","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"2025062010112412300_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jnci\/78.3.459","article-title":"Leukemia after therapy with alkylating agents for childhood cancer","volume":"78","author":"Tucker","year":"1987","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2025062010112412300_bib27","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.1015350108","article-title":"Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells","volume":"108","author":"Cao","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2025062010112412300_bib28","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3324\/haematol.2019.226936","article-title":"Human hematopoietic stem\/progenitor cells display reactive oxygen species-dependent long-term hematopoietic defects after exposure to low doses of ionizing radiations","volume":"105","author":"Henry","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"2025062010112412300_bib29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0301-472X(99)00076-4","article-title":"Stromal damage as consequence of high-dose chemo\/radiotherapy in bone marrow transplant recipients","volume":"27","author":"Galotto","year":"1999","journal-title":"Exp Hematol"},{"issue":"9-10","key":"2025062010112412300_bib30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.dnarep.2006.05.031","article-title":"Topoisomerase II and the etiology of chromosomal translocations","volume":"5","author":"Felix","year":"2006","journal-title":"DNA Repair"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2831\/2378590\/blooda_adv-2024-014728-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2831\/2378590\/blooda_adv-2024-014728-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T10:11:33Z","timestamp":1750414293000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/11\/2831\/535644\/Improved-outcomes-and-treatment-guidance-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014728","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,10]]},"published":{"date-parts":[[2025,6,10]]}}}